Try these simple tricks to improve your sleep
Well+Being
Try these simple tricks to improve your sleep
February 7, 2025 | 6:54 PM GMT
Ask a Doctor columnist Trisha Pasricha explains how making just a few adjustments could improve your sleep and health.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs
Philip Morris International Inc., a leading tobacco company, is committed to becoming a 100% smoke-free entity. By March 2025, 42% of revenue was from smoke-free products like IQOS and ZYN. The firm is advancing digital transformation and tech initiatives to enhance health-focused and prescription products. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Philip Morris International Inc. - 2025" company profile has been added to offering. The report provides insights into the Philip Morris International's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Philip Morris International Inc. (Philip Morris) is a US-based multinational tobacco company. It produces cigarettes and a variety of smoke-free products, including e-vapor, heated tobacco, and oral smokeless products. Philip Morris aims to become a 100% smoke-free products company in the near future. As of March 31, 2025, smoke-free products accounted for 42% of Philip Morris' overall revenue. The company is also focusing on developing and commercializing oral and inhaled consumer health & wellness products, as well as inhaled prescription products for cardiovascular emergencies and pain management. IQOS and ZYN are the leading smoke-free brands of the company, while Marlboro, Parliament, Chesterfield, L&M and Philip Morris are the leading cigarette report provides information and insights into Philip Morris' tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives covering partnerships and product launches. Insights on each technology initiative including technology theme, objective, and benefits. Details of estimated ICT budgets. Reasons to Buy Gain insights into Philip Morris' tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and other Innovation Programs Technology Focus Technology Initiatives Venture Arm: PM Equity Partner Partnerships Network Map ICT Budget and Contracts Key Executives For more information about this company profile visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT. The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. GERMAN BIOTECH CHAMPION The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress. CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros. BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac. The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer. ($1 = 0.8624 euros) (Additional reporting by Christian Kraemer; Editing by Friederike Heine, Jan Harvey and Emelia Sithole-Matarise)
Business Upturn
4 days ago
- Business Upturn
PhenQ Announces Official Website Update Featuring Enhanced User Experience and Easier Access to Metabolic Support Resources
Austin, June 09, 2025 (GLOBE NEWSWIRE) — PhenQ , a global wellness brand dedicated to supporting weight management and metabolic health, has officially updated its website to provide users with an improved experience and simplified access to its trusted supplement offerings. The redesign reflects PhenQ's continued focus on user accessibility, faster navigation, and easier product discovery. According to the official site ( the update introduces a streamlined homepage layout, optimized mobile responsiveness, and enhanced search features—allowing visitors to explore wellness resources, customer FAQs, and product insights with greater ease. 'We reimagined the user experience to make it easier for our community to access the information and tools they need,' said a PhenQ spokesperson. 'The updated interface ensures customers can learn about our approach to natural weight support with clarity and confidence.' The redesign also includes an upgraded checkout process, faster loading times, and an expanded Help Center. Visitors can now more efficiently explore PhenQ's educational articles, access order tracking, and engage with customer support through newly integrated live chat and FAQ navigation tools. The company states that this digital refresh is part of a broader initiative to enhance global wellness accessibility through online platforms, aligning with the brand's mission to support healthy lifestyles via intuitive, user-friendly resources. As highlighted on the website, PhenQ continues to offer a satisfaction guarantee for new customers. With improved tools and responsive support now built into the site, users can expect a more streamlined journey from education to product exploration. About PhenQ PhenQ is a globally recognized wellness brand committed to delivering natural, easy-to-integrate supplements that support metabolic health and weight management. Focused on simplicity, transparency, and digital accessibility, PhenQ empowers adults to pursue wellness goals with confidence. Product and Contact Information Brand: PhenQ Website: Email: [email protected] Phone (U.S.): +1 888-643-8434 (4am–6pm EST) Phone (UK): +44 20 4572 5840 (9am–11pm GMT) Mailing Address: 12 Payne Street, Glasgow G4 0LF, United Kingdom Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
